---
figid: PMC6312726__nihms-442942-f0007
figtitle: Model for the limitation of the ERK1/2 signal by PRMT5
organisms:
- Saccharomyces cerevisiae
- Armoracia rusticana
- Diaporthe sclerotioides
- Schizosaccharomyces pombe
- Homo sapiens
- Mus musculus
- Rattus norvegicus
- Bos taurus
- Equus caballus
- Chlorocebus aethiops
- Caenorhabditis elegans
- vectors
- Pollachius virens
organisms_ner:
- Caenorhabditis elegans
- Mus musculus
- Homo sapiens
- Arabidopsis thaliana
pmcid: PMC6312726
filename: nihms-442942-f0007.jpg
figlink: /pmc/articles/PMC6312726/figure/F7/
number: F7
caption: Model for the limitation of the ERK1/2 signal by PRMT5. Growth factors or
  mutated RAS activate CRAF and thereby the MAPK signaling pathway. PRMT5 promotes
  CRAF degradation and limits its catalytic activity, reducing the activation of downstream
  kinases, such as MEK1/2 and ERK1/2. In contrast, PRMT5 does not affect downstream
  signals in cells with BRAFV600E, which are independent of RAS. Decreasing PRMT5
  activity (pharmacologically or by its knockdown) increases the stability of activated
  CRAF, increasing the amplitude of the ERK1/2 signal and the integrated signal strength
  and consequently affecting the evoked biological response.
papertitle: Protein Arginine Methyltransferase 5 Regulates ERK1/2 Signal Transduction
  Amplitude and Cell Fate Through CRAF.
reftext: Pedro Andreu-PÃ©rez, et al. Sci Signal. 2011 Sep 13;4(190):ra58-ra58.
year: '2011'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9030331
figid_alias: PMC6312726__F7
figtype: Figure
redirect_from: /figures/PMC6312726__F7
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6312726__nihms-442942-f0007.html
  '@type': Dataset
  description: Model for the limitation of the ERK1/2 signal by PRMT5. Growth factors
    or mutated RAS activate CRAF and thereby the MAPK signaling pathway. PRMT5 promotes
    CRAF degradation and limits its catalytic activity, reducing the activation of
    downstream kinases, such as MEK1/2 and ERK1/2. In contrast, PRMT5 does not affect
    downstream signals in cells with BRAFV600E, which are independent of RAS. Decreasing
    PRMT5 activity (pharmacologically or by its knockdown) increases the stability
    of activated CRAF, increasing the amplitude of the ERK1/2 signal and the integrated
    signal strength and consequently affecting the evoked biological response.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - prmt-5
  - mek-1
  - mek-2
  - ras
  - Hras
  - Kras
  - Rem1
  - Prmt5
  - Raf1
  - Map2k1
  - Map2k2
  - Mapk3
  - Mapk1
  - Apc
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - KRAS
  - HRAS
  - NRAS
  - PRMT5
  - RAF1
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - SKB1
  - MTA
  - MEK1
  - PERK1
  - PERK12
  - PERK2
---
